Exelixis Inc (EXEL)

17.37
NASDAQ : Health Care
Prev Close 16.52
Day Low/High 16.42 / 17.74
52 Wk Low/High 3.55 / 17.74
Avg Volume 6.97M
Exchange NASDAQ
Shares Outstanding 286.46M
Market Cap 4.73B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Shark Bites: Eager Buyers Pounce on Pullback

Shark Bites: Eager Buyers Pounce on Pullback

I'm underinvested, which isn't good when indices are up.

Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor

Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor

Interpreting 'K-M curves' correctly is an important tool for biotech investors.

How to Be a Smarter Biotech Investor

How to Be a Smarter Biotech Investor

Interpreting "K-M curves" correctly is an important tool for biotech investors.

Exelixis To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29

Exelixis To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis To Present At The Stifel 2016 Healthcare Conference On November 15

Exelixis To Present At The Stifel 2016 Healthcare Conference On November 15

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech's Planned Phase 3 Pivotal Trials

Exelixis Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech's Planned Phase 3 Pivotal Trials

Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of new data from clinical trials of cobimetinib in combination with other therapies to treat forms of advanced melanoma.

Exelixis (EXEL) Stock Gains on Q3 Results

Exelixis (EXEL) Stock Gains on Q3 Results

Exelixis (EXEL) beat expectations for the third quarter.

Exelixis Announces Third Quarter And Year To Date 2016 Financial Results And Provides Corporate Update

Exelixis Announces Third Quarter And Year To Date 2016 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2016 and provided an update on progress toward delivering upon its key 2016 corporate objectives, as well as commercial and clinical...

Exelixis To Release Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Exelixis To Release Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2016 financial results will be released on Thursday, November 3, 2016 after the markets close.

Exelixis Announces Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At ESMO 2016

Exelixis Announces Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At ESMO 2016

Exelixis, Inc. (NASDAQ:EXEL) today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or...

Exelixis Announces Genentech Presentation Of Preliminary Phase 1b Results For The Combination Of Cobimetinib, Vemurafenib And Atezolizumab At ESMO 2016 Congress

Exelixis Announces Genentech Presentation Of Preliminary Phase 1b Results For The Combination Of Cobimetinib, Vemurafenib And Atezolizumab At ESMO 2016 Congress

Exelixis, Inc. (NASDAQ:EXEL) today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the...

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab In Advanced Genitourinary Tumors

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab In Advanced Genitourinary Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.

Exelixis And Ipsen To Host Investor And Media Briefing To Discuss Data Presented At The ESMO 2016 Congress

Exelixis And Ipsen To Host Investor And Media Briefing To Discuss Data Presented At The ESMO 2016 Congress

Exelixis, Inc. (NASDAQ:EXEL) today announced that the company and its partner Ipsen will jointly host a live investor and media briefing at the European Society for Medical Oncology (ESMO) 2016 Congress.

Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone

Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone

Preliminary results from Exelixis' (EXEL) CaboNivo drug trial indicated issues among nine of 24 patients participating in the study.

Exelixis Elects Julie Anne Smith To Its Board Of Directors

Exelixis Elects Julie Anne Smith To Its Board Of Directors

Exelixis, Inc. (NASDAQ: EXEL) today announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company's Board of Directors.

Exelixis Announces Collaborator Daiichi Sankyo's Initiation Of Phase 3 Clinical Development For CS-3150, A Selective Mineralocorticoid Receptor Antagonist

Exelixis Announces Collaborator Daiichi Sankyo's Initiation Of Phase 3 Clinical Development For CS-3150, A Selective Mineralocorticoid Receptor Antagonist

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone (r-INN)), an oral,...

'Mad Money' Lightning Round: Don't Sell Scripps

'Mad Money' Lightning Round: Don't Sell Scripps

Cramer says Fiserv is a winner and to pull the trigger on EPR Properties.

Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters

Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters

Focus on finding stocks of high-quality companies at good prices, Cramer advises.

Exelixis Provides Update On Timing Of Key Cabozantinib Clinical Data Presentation At The ESMO 2016 Congress

Exelixis Provides Update On Timing Of Key Cabozantinib Clinical Data Presentation At The ESMO 2016 Congress

Exelixis, Inc. (NASDAQ:EXEL) today provided an update on the timing of a key data presentation for cabozantinib at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held October 7-11, 2016 in...

2 Bullish Stock Picks and 2 Stocks to Sell Short

2 Bullish Stock Picks and 2 Stocks to Sell Short

Here's a look at two stocks that are trending higher and two that are ripe for short-selling.

Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug

Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug

Exelixis (EXEL) said today that its renal cell carcinoma drug was approved by the European Commission, allowing it to be marketed in the European Union, among other areas.

European Commission Approves CABOMETYX™ (cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

European Commission Approves CABOMETYX™ (cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission (EC) has approved CABOMETYX™ (cabozantinib) tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular...

Exelixis Announces Outcome From First Planned Interim Analysis Of The Phase 3 CELESTIAL Trial Of Cabozantinib In Patients With Advanced Hepatocellular Carcinoma

Exelixis Announces Outcome From First Planned Interim Analysis Of The Phase 3 CELESTIAL Trial Of Cabozantinib In Patients With Advanced Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced the outcome from the first planned interim analysis of CELESTIAL, a randomized global phase 3 trial of cabozantinib compared with placebo in patients with advanced hepatocellular...

Exelixis To Present At The Morgan Stanley Global Healthcare Conference On September 13

Exelixis To Present At The Morgan Stanley Global Healthcare Conference On September 13

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Exelixis-discovered Compounds To Be Featured In 15 Presentations At The ESMO 2016 Congress

Exelixis-discovered Compounds To Be Featured In 15 Presentations At The ESMO 2016 Congress

Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in...

Exelixis Stock Sees Short Interest Decrease By 29.7%

Exelixis Stock Sees Short Interest Decrease By 29.7%

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 14,515,247 share decrease in total short interest for Exelixis Inc , to 34,290,608, a decrease of 29.74% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Exelixis Announces Redemption Of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019

Exelixis Announces Redemption Of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019

Exelixis, Inc. (NASDAQ:EXEL) today announced that it has called for redemption approximately $48.

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.